Michael Friedlander Selected Research

olaparib

2/2024	Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
6/2023	Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.
1/2023	Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
12/2022	CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
10/2022	EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study).
1/2022	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
12/2021	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
10/2021	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
1/2021	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
1/2021	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Friedlander Research Topics

Disease

85	Ovarian Neoplasms (Ovarian Cancer) 02/2024 - 04/2003
64	Neoplasms (Cancer) 04/2024 - 04/2005
25	Breast Neoplasms (Breast Cancer) 02/2024 - 04/2005
19	Carcinoma (Carcinomatosis) 05/2023 - 05/2004
18	Fatigue 02/2024 - 10/2006
11	Disease Progression 01/2023 - 05/2014
10	Peripheral Nervous System Diseases (PNS Diseases) 04/2024 - 01/2015
9	Ovarian Epithelial Carcinoma 06/2023 - 03/2009
8	Anemia 06/2023 - 05/2010
8	Nausea 06/2023 - 07/2010
8	Neutropenia 01/2022 - 10/2014
4	Ascites 02/2024 - 10/2018
4	Endometrial Neoplasms (Endometrial Cancer) 12/2022 - 01/2019
4	Thrombocytopenia (Thrombopenia) 10/2021 - 10/2014
4	Vomiting 10/2021 - 04/2012
3	Fallopian Tube Neoplasms 01/2021 - 12/2018
2	Hypersensitivity (Allergy) 04/2024 - 04/2003
2	Obesity 04/2024 - 01/2022
2	Chronic Disease (Chronic Diseases) 02/2024 - 05/2010
2	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 12/2022 - 09/2011
2	Asthenia 10/2021 - 01/2017
2	Neoplasm Metastasis (Metastasis) 10/2020 - 11/2006
2	Clear Cell Adenocarcinoma 01/2020 - 04/2011
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020 - 12/2009
2	Hypertension (High Blood Pressure) 03/2016 - 10/2014
2	Residual Neoplasm 02/2015 - 03/2009
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 02/2015 - 04/2003
2	Mood Disorders (Mood Disorder) 01/2011 - 10/2006
2	Colorectal Neoplasms (Colorectal Cancer) 07/2007 - 07/2006
1	Hypesthesia (Numbness) 04/2024
1	Pancreatic Neoplasms (Pancreatic Cancer) 06/2023
1	Turcot syndrome 12/2022
1	Hyperplasia 01/2022

Drug/Important Bio-Agent (IBA)

52	PlatinumIBA 02/2024 - 04/2003
31	olaparibIBA 02/2024 - 07/2010
27	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2023 - 07/2010
22	Paclitaxel (Taxol)FDA LinkGeneric 04/2024 - 03/2009
20	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 04/2003
11	veliparibIBA 01/2024 - 02/2017
10	Biomarkers (Surrogate Marker)IBA 02/2024 - 02/2011
9	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 06/2023 - 09/2011
5	Immune Checkpoint InhibitorsIBA 12/2022 - 04/2018
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 07/2006
5	liposomal doxorubicin (Doxil)FDA Link 01/2021 - 03/2009
5	Hormones (Hormone)IBA 01/2021 - 04/2005
4	thiaclopridIBA 12/2023 - 09/2011
4	Poly Adenosine Diphosphate RiboseIBA 01/2023 - 09/2011
4	paragonIBA 10/2021 - 01/2019
4	Capsules (Microcapsules)IBA 10/2021 - 02/2016
4	TabletsIBA 01/2021 - 01/2017
4	Anastrozole (Arimidex)FDA LinkGeneric 09/2019 - 11/2014
3	AntigensIBA 01/2023 - 09/2011
3	durvalumabIBA 12/2022 - 01/2020
3	Estrogen ReceptorsIBA 09/2019 - 04/2005
3	Estrogens (Estrogen)FDA Link 09/2019 - 04/2017
3	Aromatase InhibitorsIBA 01/2019 - 10/2008
3	pazopanib FDA Link 03/2016 - 10/2010
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 04/2011
3	Cisplatin (Platino)FDA LinkGeneric 10/2013 - 04/2003
2	Bevacizumab (Avastin)FDA Link 02/2024 - 05/2014
2	human ERBB2 proteinIBA 01/2024 - 01/2021
2	rucaparibIBA 06/2023 - 01/2017
2	CreatinineIBA 01/2023 - 10/2011
2	B7-H1 AntigenIBA 12/2022 - 01/2020
2	ChromatinIBA 12/2022 - 01/2021
2	Progesterone Receptors (Progesterone Receptor)IBA 10/2020 - 09/2019
2	Phosphotransferases (Kinase)IBA 01/2020 - 02/2019
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 12/2019 - 04/2012
2	Adenosine Diphosphate (ADP)IBA 12/2019 - 04/2012
2	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 12/2018 - 12/2009
2	Tamoxifen FDA LinkGeneric 01/2017 - 11/2014
2	Gemcitabine FDA Link 01/2015 - 03/2009
2	Angiogenesis InhibitorsIBA 04/2011 - 10/2010
2	Proteins (Proteins, Gene)FDA Link 03/2008 - 12/2004
1	LipidsIBA 04/2024
1	Triglycerides (Triacylglycerol)IBA 04/2024
1	Cell-Free Nucleic AcidsIBA 02/2024
1	ErbB Receptors (EGF Receptor)IBA 02/2024
1	niraparibIBA 06/2023
1	Indicators and Reagents (Reagents)IBA 01/2023
1	Analgesics (Analgesic Drugs)IBA 01/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2023
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2023
1	CBLC137IBA 12/2022
1	AlpelisibIBA 10/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022

Therapy/Procedure

71	Drug Therapy (Chemotherapy) 04/2024 - 04/2003
59	Therapeutics 02/2024 - 10/2006
5	Adjuvant Chemotherapy 02/2024 - 11/2006
5	Aftercare (After-Treatment) 01/2022 - 08/2007
4	Radiotherapy 02/2024 - 04/2003
3	Mastectomy (Mammectomy) 01/2022 - 07/2012
3	Cytoreduction Surgical Procedures 01/2015 - 10/2010
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 05/2015
2	Neoadjuvant Therapy 08/2016 - 02/2015
2	Hysterectomy 02/2015 - 11/2013
2	Salpingo-oophorectomy 07/2012 - 04/2004
1	Retreatment 04/2024
1	Drug Tapering 04/2024
1	Subcutaneous Mastectomy 01/2022